コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 -2 only) and immediately after completion of antirejection therapy.
2 episodes of acute rejection and response to antirejection therapy.
3 ting grafts could be targeted for additional antirejection therapy.
4 he urine increases in response to successful antirejection therapy.
5 uld permit the assessment of the efficacy of antirejection therapy.
6 transplanted intestine, and the response to antirejection therapy.
7 steroid and OKT3 resistance within 48 hr of antirejection therapy.
8 MSCs may serve as a new, safe, and effective antirejection therapy.
9 evel of HCV RNA and genotype and the type of antirejection therapy.
10 te rejection, and decreased after successful antirejection therapy.
11 cute rejection, with a subsequent rise after antirejection therapy.
12 nal antibody or gallium nitrate was used for antirejection therapy, (2) this immune status is charact
16 outcome and novel therapeutic approaches for antirejection therapy based on targeting of chemokines a
17 for graft loss, and the initial response to antirejection therapy can predict long-term graft outcom
18 plasma (BKP) (group 1) and also tried other antirejection therapies in 13 patients with BK virus in
21 ositive UFCs that completely normalized with antirejection therapy (n=8); group III--stable patients
22 reviewed the clinical course and response to antirejection therapy of 24 patients with borderline cha
24 harge and at time of AR before initiation of antirejection therapy or at matching timepoints in patie
25 acute rejection showed complete response to antirejection therapy (P=0.25 vs. patients with borderli
31 esponse, partial response and no response to antirejection therapy were observed in 16/24 (66.7%), 3/
32 sAMRV), and AMRV showed similar responses to antirejection therapy, whereas the grafts with v2- or v3
33 safe and allows the avoidance of unnecessary antirejection therapy with its attendant side effects an
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。